JP2014510156A - レイノー病を治療する方法および組成物 - Google Patents

レイノー病を治療する方法および組成物 Download PDF

Info

Publication number
JP2014510156A
JP2014510156A JP2014504039A JP2014504039A JP2014510156A JP 2014510156 A JP2014510156 A JP 2014510156A JP 2014504039 A JP2014504039 A JP 2014504039A JP 2014504039 A JP2014504039 A JP 2014504039A JP 2014510156 A JP2014510156 A JP 2014510156A
Authority
JP
Japan
Prior art keywords
composition
prostaglandin
raynaud
dimethylamino
semi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510156A5 (enExample
Inventor
フランク，ダニエル，ダブリュー．
マーティン，リチャード
ダマジュ，バッサム，ビー．
Original Assignee
ネクスメッド ホールディングス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクスメッド ホールディングス，インコーポレイテッド filed Critical ネクスメッド ホールディングス，インコーポレイテッド
Publication of JP2014510156A publication Critical patent/JP2014510156A/ja
Publication of JP2014510156A5 publication Critical patent/JP2014510156A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014504039A 2011-04-07 2012-04-06 レイノー病を治療する方法および組成物 Pending JP2014510156A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472988P 2011-04-07 2011-04-07
US61/472,988 2011-04-07
PCT/US2012/032577 WO2012139033A1 (en) 2011-04-07 2012-04-06 Methods and compositions for treating raynaud's disease

Publications (2)

Publication Number Publication Date
JP2014510156A true JP2014510156A (ja) 2014-04-24
JP2014510156A5 JP2014510156A5 (enExample) 2015-04-23

Family

ID=46969575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504039A Pending JP2014510156A (ja) 2011-04-07 2012-04-06 レイノー病を治療する方法および組成物

Country Status (8)

Country Link
US (4) US8940794B2 (enExample)
EP (1) EP2693877A4 (enExample)
JP (1) JP2014510156A (enExample)
BR (1) BR112013025744A2 (enExample)
CA (1) CA2838109C (enExample)
MX (1) MX342511B (enExample)
RU (1) RU2633236C2 (enExample)
WO (1) WO2012139033A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608378A1 (en) 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
CN109288848A (zh) * 2018-11-27 2019-02-01 西安力邦肇新生物科技有限公司 前列腺素e1甲酯在制备扩张血管药物中的应用
WO2022032141A1 (en) 2020-08-07 2022-02-10 Eicos Sciences, Inc. Method of treating systemic sclerosis with symptomatic raynaud's phenomenon by intravenous or subcutaneous iloprost administration
WO2025019625A1 (en) 2023-07-18 2025-01-23 Btg International Inc. Method of using iloprost for treating frostbite

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63246331A (ja) * 1987-02-16 1988-10-13 ジュルゲン・ツェー・フルーリッヒ プロスタグランジンｅ↓１誘導体含有医薬組成物
JP2002544240A (ja) * 1997-11-05 2002-12-24 ネックスメド ホールディングス インコーポレイテッド プロスタグランジンｅ１運搬用の局所用組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029814A (en) 1975-12-29 1977-06-14 The Upjohn Company Phenyl-substituted prostaglandin-e type analogs
US4212987A (en) 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE1 analogs
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4820732A (en) 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
US5219885A (en) 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
ATE141794T1 (de) 1991-03-14 1996-09-15 R Tech Ueno Ltd Stimulierung von wundheilung mit 15-keto- prostaglandinverbindungen
WO1993015739A1 (fr) 1992-02-07 1993-08-19 Kaken Pharmaceutical Co., Ltd. Remede destine aux blessures ou aux hemorroides
WO1995009590A1 (en) 1993-10-07 1995-04-13 Odontex, Inc. Absorption enhancers for topical pharmaceutical formulations
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US20020165122A1 (en) 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US5952006A (en) 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
TW473834B (en) 1998-05-01 2002-01-21 Ibm Method of doping a gate and creating a very shallow source/drain extension and resulting semiconductor
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US7087240B1 (en) 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
CA2442479C (en) 1999-05-13 2005-12-13 Nexmed Holdings, Inc. Topical compositions for prostaglandin e1 delivery
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
CN1416341B (zh) 2000-02-04 2010-05-05 武田药品工业株式会社 稳定的乳液组合物
AU2002317041A1 (en) 2002-07-24 2004-02-09 Snp Natural Products Pty Ltd TOPICAL ANTIINFLAMMATORY PREPARATIONS OF Gamma-TERPINENE
EP1558614B1 (en) 2002-10-30 2010-09-01 Merck Frosst Canada Ltd. Pyridopyrrolizine and pyridoindolizine derivatives
US20050181030A1 (en) 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
US6841574B2 (en) 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
EP1608378A1 (en) 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
CA2665081C (en) * 2006-10-02 2015-12-01 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
EP2011496A1 (en) 2007-07-03 2009-01-07 Indena S.P.A. Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63246331A (ja) * 1987-02-16 1988-10-13 ジュルゲン・ツェー・フルーリッヒ プロスタグランジンｅ↓１誘導体含有医薬組成物
JP2002544240A (ja) * 1997-11-05 2002-12-24 ネックスメド ホールディングス インコーポレイテッド プロスタグランジンｅ１運搬用の局所用組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015050590; 全身性強皮症診療ガイドライン , 201010, ｐ．７１-８０, 強皮症調査研究班事務局 *

Also Published As

Publication number Publication date
US8940794B2 (en) 2015-01-27
US20160081954A1 (en) 2016-03-24
RU2013141836A (ru) 2015-05-20
CA2838109A1 (en) 2012-10-11
US20140200274A1 (en) 2014-07-17
WO2012139033A1 (en) 2012-10-11
US9855231B2 (en) 2018-01-02
EP2693877A4 (en) 2014-11-19
US9517218B2 (en) 2016-12-13
US20180333377A1 (en) 2018-11-22
RU2633236C2 (ru) 2017-10-11
BR112013025744A2 (pt) 2016-08-16
US10632086B2 (en) 2020-04-28
CA2838109C (en) 2020-06-09
MX2013011662A (es) 2013-12-12
EP2693877A1 (en) 2014-02-12
US20160331761A1 (en) 2016-11-17
MX342511B (es) 2016-10-03

Similar Documents

Publication Publication Date Title
US10632086B2 (en) Methods and compositions for treating Raynaud's disease
KR100614361B1 (ko) 남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법
EP0436217B1 (en) Anti-inflammatory analgesic patch
JP4544859B2 (ja) 男性勃起機能不全の治療のためのプロスタグランジン組成物
AU2003220786B2 (en) Orodispersible pharmaceutical composition comprising agomelatine
US20050042173A1 (en) Micronized film-forming powder comprising an active substance
HU229083B1 (en) Compositions and methods for amelioration of human female sexual dysfunction
US20020187169A1 (en) Kavalactone compositions
AU2024204716A1 (en) Treatment of alopecia areata
JP7134097B2 (ja) 神経障害性疼痛の治療のための低用量ｆｌｔ３受容体阻害剤
Kaleli et al. Symptomatic treatment of premenstrual mastalgia in premenopausal women with lisuride maleate: a double-blind placebo-controlled randomized study
Capuano et al. Cardiovascular, respiratory, thermoregulatory, sedative, and analgesic effects of intravenous administration of medetomidine in rhesus macaques (Macaca mulatta)
US20060189695A1 (en) External preparation for improving coital function
Muenter et al. PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent
US20150320764A1 (en) Treating female sexual arousal disorder and related symptoms
JP3889456B2 (ja) グリセロリン酸脱水素酵素阻害剤
JPWO2003094917A1 (ja) ビントペロール含有経皮投与用医薬組成物
CN117582424A (zh) 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US20120035265A1 (en) Compositions, methods, and devices for the treatment of dysmenorrhea
JPH0959149A (ja) 消炎鎮痛組成物
JP2022067848A (ja) 経鼻投与用医薬組成物
TW202214224A (zh) 多汗症治療用之外用液劑
EP4132532A1 (en) Topical use of erlotinib for treating keratodermas in children
JP2020172475A (ja) メロキシカム又はその薬学的に許容される塩を含有する内服治療剤
JPWO2009139213A1 (ja) プロクロルペラジン含有外用医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180827